KEY POINTS
- This case report from the Maria Sklodowska-Curie National Research Institute of Oncology, Poland, describes an adult woman with metastatic dedifferentiated osteosarcoma involving the cervical and thoracic spine. Following primary femoral surgery, multiple lines of chemotherapy, repeated spinal operations and tumor progression, additional radiotherapy was delivered to recurrent or oligoprogressive vertebral disease. The patient had extensive previous treatment and progressive systemic metastases, representing a highly selected salvage setting.
- Three stereotactic spinal radiotherapy courses were delivered between July 2019 and December 2022. The first treatment prescribed 27 Gy in three fractions to the postoperative T2 region. A second course in January 2022 used 32.5/45 Gy in ten fractions for recurrent thoracic disease, followed by a third course in December 2022 delivering 30/35 Gy in five fractions to cervical and upper thoracic disease. Treatments used VMAT, CBCT guidance and MRI/CT-based target delineation.
- Cumulative spinal cord dose was evaluated using biologically effective dose with α/β = 2 Gy. Following the repeated irradiation courses, reported cumulative BED values for the spinal cord were 149 Gy for Dmax and 120.6 Gy for D0.035cm³, compared with 173 and 161 Gy, respectively, for the spinal cord with a 2-mm margin. These values were derived from treatment-planning calculations incorporating previous courses; they should not be interpreted as universally acceptable spinal cord retreatment constraints.
- A partial radiological response was observed after the third irradiation course, with regression of cervical/upper thoracic lesions documented approximately three months later. Regression of pulmonary lesions was also reported, but the patient had received additional systemic treatment, including paclitaxel, preventing attribution of distant responses to irradiation. The case report provides no standardized actuarial local control estimate or independently confirmed duration of spinal response.
- No acute adverse events were reported immediately after the third course, but subsequent clinical deterioration was substantial. The patient developed severe pain and limb weakness associated with mechanical complications of previous spinal stabilization, including loosening of fixation screws and vertebral damage. Additional surgery was required in March 2023, involving extensive posterior stabilization and osteotomy. The contribution of repeated irradiation versus tumor progression and prior surgery could not be established.
- The patient subsequently experienced continued advanced disease and died in February 2024. Formal longitudinal quality-of-life assessments were unavailable, and the report did not demonstrate sustained neurological recovery, independent functional improvement or durable disease control. The authors emphasize the importance of multidisciplinary review, cumulative spinal cord dose calculation and careful assessment of previous radiotherapy and surgical interventions.
- The principal limitation is the single-case design combined with complex overlapping treatments. Disease progression, multiple surgical procedures, spinal hardware failure, systemic treatments and uncertainties in time-dependent neural tissue recovery make both efficacy and toxicity attribution difficult. Additionally, the described treatment levels and discussion of repeated irradiation at the same spinal level are not entirely consistent across sections, limiting precise interpretation of cumulative geometric overlap.
CLINICAL TAKEAWAY
Repeated stereotactic irradiation may be technically possible in carefully selected patients with recurrent spinal osteosarcoma when surgery and systemic treatment options are limited. However, this case demonstrates only short-term radiological response in a highly complex clinical setting and cannot establish the long-term safety, neurological benefit or optimal dose constraints of multiple spinal reirradiation courses.